

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 8, 2012

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-32085
(Commission
File Number)

36-4392754
(IRS Employer
Identification No.)

222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (312) 506-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 hereto is an Investor Presentation dated May 8, 2012, which is incorporated herein by reference.

The information contained in or incorporated into this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation dated May 8, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: May 8, 2012

By: /s/ William J. Davis
William J. Davis
Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation dated May 8, 2012

May 2012

Allscripts Investor Presentation




Forward-Looking Statement

This presentation contains forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties. We develop forward-looking statements by combining currently available information with our beliefs and assumptions. These statements relate to future events, including our future performance, and management's expectations, beliefs, intentions, plans or projections relating to the future and some of these statements can be identified by the use of forward-looking terminology such as "believes," "expects," "anticipates," "estimates," "projects," "intends," "seeks," "future," "continue," "contemplate," "would," "will," "may," "should," and the negative or other variations of those terms or comparable terminology or by discussion of strategy, plans, opportunities or intentions. As a result, actual results, performance or achievements may vary materially from those anticipated by the forward-looking statements. Among the factors that could cause actual results, performance or achievements to differ materially from those indicated by such forward-looking statements are: the possibility that the expected synergies, efficiencies and cost savings of the merger with Eclipsys Corporation ("Eclipsys") will not be realized, or will not be realized within the expected time period; potential difficulties or delays in achieving platform and product integration and the connection and movement of data among hospitals, physicians, patients and others; the risk that the Allscripts and Eclipsys businesses will not be integrated successfully; competition within the industries in which we operate, including the risk that existing clients will switch to products of competitors; failure to achieve certification under the Health Information Technology for Economic and Clinical Health Act could result in increased development costs, a breach of some customer obligations and could put us at a competitive disadvantage in the marketplace; the volume and timing of systems sales and installations, the impact of the reorganization of our sales and services organization; the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products or other product quality issues; the outcome of any legal proceeding that has been or may be instituted against us; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties. See our Report on Form 10-K for the year ended December 31, 2011 and our subsequent filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.

OUR VISION

A Connected Community of Health™

Allscripts is a leading provider of Electronic Health Record, practice management and other clinical, revenue cycle, connectivity and information solutions for physicians, hospitals & post-acute organizations



Allscripts: Who We Are

OUR CLIENTS

- 180,000 Physicians
- 50,000 Physician Practices
- 1,500 Hospitals
- 10,000 Post-acute Facilities
- 27,000 Clinicians In Patients Homes Every Day

OUR COMPANY

- ~\$1.444BB 2011 Revenue
- 6,700 Employees
- ~\$190MM 2012 R&D¹ Run Rate
- Leader in Innovation
- 1 Complete Set of Solutions

¹Total research and development costs before software capitalization.

Investment Highlights

MARKET LEADER • Diverse, industry-leading client base

COMPLETE PRODUCT PORTFOLIO • Flexible, modern and complete solutions
• Maximizes opportunities to expand market and wallet share

DYNAMIC GROWTH MARKET • \$30BB Federal stimulus program drives healthcare IT adoption
• Low penetration of clinical solutions
• Shift to value-based care drives strong long-term secular demand trends

OPERATING LEVERAGE • Proven and scalable platform for sales growth
• Legacy of product innovation
• Industry-leading brand awareness

HIGH QUALITY FINANCIAL MODEL • Strong visibility with \$2.9BB revenue backlog as of 3/31/12
• ~69% recurring revenue in Q1 2012
• Strong free cash flow


Agenda



MARKET



DIFFERENTIATION



GROWTH





Market: The Time is NOW

A National Problem

- Quality Issues
- Medical Errors / Safety Concerns
- Rising Cost
- Significant Waste



A Market that is Ready

- \$43BB¹ Opportunity
- \$30BB in Stimulus Funding
- ~35% Penetration in Physician Practices
- Rise in Employed Physicians
- Hospitals Driving Adoption



A Significant Opportunity

- We are at the *beginning* of what we expect will be the single fastest transformation of any industry in US history

1. McKinsey & Company

Market: Unsustainable Trend Requiring Change



Source: HFMA "Value in Healthcare: Current State & Future Directions June 2011"

Market: MDRX Addresses the Entire Market Opportunity

Acute/Ambulatory EHR Opportunity 2010-2014 = ~\$43BB



Source: McKinsey & Company

Market: Significant Ambulatory Potential

PRACTICE SIZE	TOTAL # OF PRACTICES	EHR PENETRATION (July '11)
1-3 Physicians	~186,000	~30%
4-9 Physicians	~28,000	~50%
10-25 Physicians	~6,900	~70%
26+ Physicians	~1,750	~85%
Total	226,650	~35%

Source: SK&A Information Services

Market: Acute Care Growth Drivers

HOSPITALS/HEALTH SYSTEMS

LEGACY REPLACEMENT CYCLE

- Obsolete mainframe systems
- Integrate acute/ambulatory systems
- Care coordination

UNDER- UTILIZATION

- Only ~20%* of hospitals at HIMSS Stage 4 adoption or higher
- Only 1%* at HIMSS Stage 7

Source: HIMSS Analytics EMR Adoption Model, July 2011




Differentiation: Leading Footprint Across the Market




Source: Percentages determined based on GAAP revenues included in Allscripts' Annual Report on Form 10-K for the year ended December 31, 2011.


Differentiation: Open and Connected Portfolio



Differentiation: The Challenge to Deliver Meaningful Care




Differentiation: The New Architecture of Healthcare



Differentiation: Allscripts Approach

- Key stakeholders across the community (Allscripts Referral Network, Allscripts Community)
- All points of care and all applications within their organization



Differentiation: Clinical Outcomes Experience and Focus

THE ADVISORY BOARD COMPANY (APRIL 2011, "A PERSPECTIVE ON THE COMPANY")

“Clinical outcomes is the name of the game in ACOs. This is an area where we believe Allscripts holds a market lead, and needs to continue to focus on delivering more integrated outcomes modules for its client base.”

Differentiation: Deliver Solutions in a Value-Based Care Environment




Differentiation: Innovative Solutions

Mobile Platforms Accelerate Adoption







Growth: Long-Term Focus




Growth: Historical Performance



- **Non-GAAP Revenue**
CY 2010:
\$1,300MM




- **Non-GAAP Revenue**¹
CY 2011 :
\$1,465MM



1. Percentages determined based on GAAP revenues included in Allscripts' Annual Report on Form 10-K for the year ended December 31, 2011.

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

Growth: Distribution Outpaces the Competition




Growth: Cost Synergy Opportunities


Key Cost Synergy Drivers

- Duplicative management structure
- Duplicative public company costs
- Duplicative back-end office and system integration
- Marketing

Projected Cost Synergies Over Three Years



Growth: Significant Client Sales Opportunity



Business Update

- **Q1 Results**

- Bookings \$194.6MM
- Three new Sunrise Clinical Manager sales
- Non-GAAP revenue growth 6%
- Non-GAAP operating profit margin 11.2%
- Non-GAAP EPS \$0.12
- Cash Flow From Operations \$74.6MM

- **Factors Impacting Results**

- Lower Q1 sales
- Unfavorable revenue mix
- Investments in R&D & lower capitalized software:
 - Gross R&D +29% year/year
 - Software Capitalization 27% in Q1 2012 vs. 40% in Q1 2011

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

Four Point Plan

Product Delivery

- **\$190MM 2012 gross R&D spend**
- **New product releases**
- **Innovation**

Client Experience

- **Added 400 support FTEs**
- **\$30MM invested in solutions hosting**
- **Improve key metrics tied to client experience**

Sales Execution

- **Sales/service integration**
- **Single corporate leadership**
- **Single client team**
- **Increase pipeline size, velocity**

Financial Performance

- **Further enhance operational efficiency**
- **Expanded share repurchase plan to \$400MM**
- **Completed majority of hiring for 2012**

Non-GAAP Financial Outlook

(\$ in millions; except per share amounts)

	CY 2011 ACTUAL	CY 2012 ¹
NON-GAAP REVENUE	\$1,465	\$1,480-\$1,520
NON-GAAP OPERATING MARGIN	20%	16-17%
NON-GAAP NET INCOME	\$176	\$143-\$154
NON-GAAP DILUTED EPS	\$0.92	\$0.74-\$0.80

Note: Guidance provided by the company in a press release on April 26, 2012. This presentation does not subsequently update or reaffirm Allscripts financial guidance. Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

Utilize Strong Cash Flow to Enhance Value

CAPITALIZATION	ACTUAL 3/31/2012 \$ in millions
Cash and Marketable Securities	\$177
Revolver (\$250mm)	0
Term Loan	343
Total Debt	\$343
Equity	1,490
Total Capitalization	\$1,833
Credit Statistics	
LTM EBITDA ⁽¹⁾	\$311
Total Debt / LTM EBITDA ⁽¹⁾	1.1x
Debt / Capitalization	18.7%

- Reduced debt by \$227MM since merger closed (8/10)
- Minimum required principal payments over next 12 months totals \$48MM
- Current borrowing cost <3%
- \$200MM, 3-year share repurchase program instituted in the second quarter of 2011
- Expanded program to \$400MM on 4/30/2012
- \$348MM remains for repurchase as of 4/30/2012

1. EBITDA is calculated as net income plus income tax expense, interest expense, stock-based compensation expense, depreciation & amortization, deferred revenue adjustments, certain one-time and transaction-related expenses, and non-recurring losses on the sale of investments minus non-recurring gains on the sale of assets, consistent with the calculation as defined in the Company's Senior Credit Facilities agreement.

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation.

In Summary....



MAY 2012

Allscripts Investor Presentation



Appendix: Non-GAAP Reconciliations

Slide and Financial Measure	GAAP-Non-GAAP Reconciliation
Slide 24: 2010 Non-GAAP Revenue, Operating Income	Slide 35, 36
Slide 24: 2011 Non-GAAP Revenue, Operating Income	Slide 38
Slide 29: Q1 2012 Non-GAAP Revenue, Operating Income Margin and Diluted Earnings Per Share	Slide 37
Slide 31: 2011 Non-GAAP Revenue, Operating Income, and Diluted Earnings Per Share	Slide 38
Slide 32: Trailing Twelve Months EBITDA	Slide 39

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue and net income reconciliation for the twelve months ended December 31, 2010

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - 2010 Financial Information
(In millions, except per-share amounts)
(unaudited)

	Three Months Ended 3/31/10			Three Months Ended 6/30/10			Three Months Ended 9/30/2010			Three Months Ended 12/31/2010	Twelve Months Ended 12/31/2010	
	Allscripts	Eclipsys	Q1 2010	Allscripts	Eclipsys	Q2 2010	Allscripts	Eclipsys	Additional Int Exp(a)	Q3 2010	Q4 2010	CY 2010
Total revenue, as reported	\$184.4	\$128.4	\$312.8	\$191.4	\$134.4	\$325.8	\$191.2	\$51.2	\$0.0	\$242.4	\$316.2	\$1,197.2
Deferred revenue adjustment	0.5	0.0	0.5	0.6	0.0	0.6	0.5	6.7	0.0	7.2	20.9	29.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	79.5	0.0	79.5	0.0	79.5
Total non-GAAP revenue	<u>\$184.9</u>	<u>\$128.4</u>	<u>\$313.3</u>	<u>\$192.0</u>	<u>\$134.4</u>	<u>\$326.4</u>	<u>\$191.7</u>	<u>\$137.4</u>	<u>\$0.0</u>	<u>\$329.1</u>	<u>\$337.1</u>	<u>\$1,305.9</u>
Net income, as reported	\$18.6	\$5.4	\$24.0	\$13.1	\$1.6	\$14.7	\$5.4	(\$4.0)	\$0.0	\$1.4	(\$6.2)	\$33.9
Deferred revenue adjustment	0.3	0.0	0.3	0.3	0.0	0.3	0.3	4.0	0.0	4.3	12.7	17.6
Acquisition-related amortization	3.4	1.9	5.3	3.5	1.8	5.3	3.4	3.0	0.0	6.4	10.6	27.6
Stock-based compensation expense	2.4	3.4	5.8	1.8	2.9	4.7	4.0	0.0	0.0	4.0	2.3	16.8
Transaction-related expense	0.1	0.0	0.1	7.7	2.0	9.7	16.0	5.5	(1.9)	19.6	10.9	40.3
ARS Sales	0.0	0.0	0.0	0.0	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.9
Tax rate alignment	0.7	0.0	0.7	(0.2)	0.0	(0.2)	(1.6)	(0.2)	0.0	(1.8)	8.4	7.1
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	2.9	0.0	2.9
Non-GAAP net income	<u>\$25.5</u>	<u>\$10.7</u>	<u>\$36.2</u>	<u>\$26.2</u>	<u>\$9.2</u>	<u>\$35.4</u>	<u>\$27.5</u>	<u>\$11.2</u>	<u>(\$1.9)</u>	<u>\$36.8</u>	<u>\$38.7</u>	<u>\$147.1</u>

(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP operating income reconciliation by quarter and twelve months ended December 31, 2010

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - 2010 Financial Information
(In millions, except per-share amounts)
(unaudited)

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended	Twelve Months Ended	
	3/31/10			6/30/10			9/30/2010			12/31/2010	12/31/2010	
	Allscripts	Eclipsys	Q1 2010	Allscripts	Eclipsys	Q2 2010	Allscripts	Eclipsys	Additional Int Exp(a)	Q3 2010	Q4 2010	CY 2010
Operating income, as reported	\$32.0	\$10.7	\$42.7	\$20.5	\$5.4	\$25.9	\$6.0	(\$7.2)	\$0.0	(\$1.2)	\$9.5	\$76.9
Deferred revenue adjustment	0.5	0.0	0.5	0.6	0.0	0.6	0.5	6.7	0.0	7.2	20.9	29.2
Acquisition-related amortization	5.6	3.1	8.7	5.6	3.1	8.7	5.6	4.9	0.0	10.5	17.4	45.3
Stock-based compensation expense	3.9	3.7	7.6	2.9	3.7	6.6	6.6	0.0	0.0	6.6	3.7	24.5
Transaction-related expense (a)	0.2	0.0	0.2	12.5	3.5	16.0	26.1	9.1	0.0	35.2	17.8	69.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	4.7	0.0	4.7
Total non-GAAP operating income	<u>\$42.2</u>	<u>\$17.5</u>	<u>\$59.7</u>	<u>\$42.1</u>	<u>\$15.7</u>	<u>\$57.8</u>	<u>\$44.8</u>	<u>\$18.2</u>	<u>\$0.0</u>	<u>\$63.0</u>	<u>\$69.3</u>	<u>\$249.8</u>

(a) Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees and other integration-related expenses, incurred in connection with announced transactions.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP Revenue, operating income margin and net income reconciliation for the three months ended March 31, 2012

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

	Three Months Ended 3/31/12	Three Months Ended 3/31/11
Total revenue, as reported	\$364.7	\$335.3
Deferred revenue adjustment	0.8	10.8
Total non-GAAP revenue	\$365.5	\$346.1
Gross profit, as reported	\$155.7	\$159.8
Deferred revenue adjustment	0.8	10.8
Total non-GAAP gross profit	\$156.5	\$170.6
Operating income, as reported	\$13.0	\$24.5
Deferred revenue adjustment	0.8	10.8
Acquisition-related amortization	16.4	16.7
Stock-based compensation expense	7.7	7.0
Transaction-related expenses (a)	3.0	13.1
Total non-GAAP operating income	\$40.9	\$72.1
Net income, as reported	\$5.8	\$12.6
Deferred revenue adjustment	0.5	6.6
Acquisition-related amortization	10.4	10.2
Stock-based compensation expense	4.9	4.3
Transaction-related expenses (a)	1.9	9.2
Tax rate alignment	0.0	(2.3)
Non-GAAP net income	\$23.5	\$40.6
Earnings per share - diluted, as reported	\$0.03	\$0.07
Non-GAAP earnings per share - diluted	\$0.12	\$0.21

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue, operating income, net income and diluted earnings per share reconciliation for the twelve months ended December 31, 2011

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information - 2011 Non-GAAP Financial Information

(In millions, except per-share amounts)
(unaudited)

	<u>Three Months Ended 3/31/11</u>	<u>Three Months Ended 6/30/11</u>	<u>Three Months Ended 9/30/11</u>	<u>Three Months Ended 12/31/2011</u>	
					CY 2011
Total revenue, as reported	\$335.3	\$356.8	\$363.7	\$388.2	\$1,444.1
Deferred revenue adjustment	10.8	6.7	2.6	1.0	21.1
Total non-GAAP revenue	\$346.1	\$363.5	\$366.3	\$389.2	\$1,465.2
Operating income, as reported	\$24.5	\$32.1	\$34.4	\$45.6	\$136.5
Deferred revenue adjustment	10.8	6.7	2.6	1.0	21.1
Acquisition-related amortization	16.7	16.6	16.6	16.5	66.4
Stock-based compensation expense	7.0	8.9	9.9	11.6	37.4
Transaction-related expenses	13.1	10.2	8.8	4.0	36.1
Total non-GAAP operating income	\$72.1	\$74.5	\$72.3	\$78.6	\$297.5
Net income, as reported	\$12.6	\$15.9	\$19.1	\$26.0	\$73.6
Deferred revenue adjustment	6.6	4.1	1.7	0.6	13.0
Acquisition-related amortization	10.2	10.1	11.0	10.5	41.7
Stock-based compensation expense	4.3	5.4	6.5	7.4	23.6
Transaction-related expenses	9.2	6.2	5.8	2.5	23.7
Tax rate alignment	(2.3)	0.8	1.1	0.7	0.3
Non-GAAP net income	\$40.6	\$42.5	\$45.2	\$47.6	\$175.9
Tax Rate	39%	39%	34%	36%	37%
Weighted shares outstanding - diluted	192.6	193.2	191.5	192.3	191.0
Earnings per share - diluted	\$0.06	\$0.08	\$0.10	\$0.14	\$0.39
Non-GAAP earnings per share - diluted	\$0.21	\$0.22	\$0.24	\$0.25	\$0.92

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP EBITDA reconciliation for the year ended March 31, 2012

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

EBITDA Calculation (\$ in thousands)	For the 12 months ended 3/31/12
Net income, as reported	\$66.8
Income tax expense	43.2
Stock-based compensation expense	39.7
Depreciation and Amortization	131.5
Interest expense	16.7
Transaction-related expenses	1.9
Deferred revenue adjustment	11.1
Gain on Sale of Assets	(0.3)
Earnings before interest, taxes, depreciation and amortization	\$310.6

Footnotes Regarding Financial Guidance

Financial guidance was last provided by the company in a press release on April 26, 2012. This presentation does not subsequently update or reaffirm Allscripts financial guidance.

Allscripts non-GAAP guidance for calendar year 2012 assumes the following adjustments to GAAP revenue, operating and net income: an acquisition-related deferred revenue adjustment of approximately \$2.1 million; approximately \$63.0 million of acquisition-related amortization; approximately \$44.0 million in stock-based compensation expense; and approximately \$4.0 million in transaction-related expenses, all on a pre-tax basis.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this release non-GAAP revenue, gross profit, operating income and net income, including non-GAAP net income on a per share basis, which are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Non-GAAP revenue consists of GAAP revenue as reported and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Non-GAAP gross profit consists of GAAP gross profit as reported and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Non-GAAP operating income consists of GAAP operating income as reported and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense, transaction-related and non-recurring expenses. Non-GAAP net income consists of GAAP net income as reported, excludes acquisition-related amortization, stock-based compensation expense and transaction-related and non-recurring expenses, and adds back the acquisition-related deferred revenue, in each case net of any related tax effects. Non-GAAP net income also includes a tax rate alignment adjustment.

Management also believes that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis provide useful supplemental information to management and investors regarding the underlying performance of the Company's business operations and facilitates comparisons of the separate 2010 pre-merger results of legacy Allscripts and legacy Eclipsys to that of the Company's 2010 post-merger results. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that we have provided and discussed herein. Management also uses this information internally for forecasting and budgeting as it believes that these measures are indicative of the Company's core operating results. In addition, the Company uses non-GAAP revenue, operating income and/or net income to measure achievement under the Company's stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis are performance measures only, and they do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

MAY 2012

Allscripts Investor Presentation

